E-ISSN 2218-6050 | ISSN 2226-4485
 

Original Article


Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner

Robert Philip Lavan, Robert Armstrong, Hannah Newbury, Dorothy Normile, Celine Hubinois.


Cited By:6

Abstract
Abstract
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically applied systemic ectoparasiticide approved for dosing at up to 12-week intervals for flea and tick control in cats.
Aim: To assess the experiences of cat owners in the U.S., U.K., or France with flea and tick control, specifically to determine the impact of 12-week fluralaner dosing on user satisfaction, product preference, and adherence to dosing recommendations compared to flea and tick medications administered monthly.
Methods: Clients of participating veterinary practices in the U.S., U.K., or France who were visiting the clinic for a routine wellness visit and currently treating their cat with fluralaner (Bravecto®) were asked to complete a short two-page survey about their experience with flea and tick medications including fluralaner and other products they may have administered.
Results: Owners in the U.S. (451 cats), U.K. (512 cats), and France (520 cats) completed surveys. Most cat owners (66-75%) had previously administered other flea and tick products. More than 94% of cat owners surveyed in each country were satisfied or very satisfied with fluralaner. The most frequently reported benefit of using fluralaner was the 12-week dosing interval, selected by 76% of respondents in the U.S., 82% in the U.K., and 70% in France. 79-88% of cat owners (depending on country) thought that dosing with extended duration fluralaner was more convenient than dosing with monthly flea and tick products and 86-89% of cat owners that had used other flea and tick products preferred fluralaner over the other flea and tick products.
Conclusion: Veterinarians in the US, UK and France recommended 12 months of flea protection and 9-11 months of tick protection per year, even though, in this study, cat owners usually purchased 1-3 months of protection per year. A longer flea and tick dosing interval, as seen with fluralaner, correlates with higher user satisfaction and preference among cat owners. Owners identified the 12-week dosing interval and single dose efficacy as the top reasons for selecting the fluralaner product for their cat. In all three countries, most cat owners indicated that they were more likely to deliver doses of extended duration fluralaner on time, compared to flea and tick products dosed monthly.

Key words: Cats, Ectoparasites, Fleas, Fluralaner, Ticks


 
ARTICLE TOOLS
Abstract
PDF Fulltext
HTML Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Robert Philip Lavan
Articles by Robert Armstrong
Articles by Hannah Newbury
Articles by Dorothy Normile
Articles by Celine Hubinois
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Lavan RP, Armstrong R, Newbury H, Normile D, Hubinois C, . Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner. Open Vet J. 2021; 11(3): 458-467. doi:10.5455/OVJ.2021.v11.i3.19


Web Style

Lavan RP, Armstrong R, Newbury H, Normile D, Hubinois C, . Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner. https://www.openveterinaryjournal.com/?mno=70389 [Access: March 13, 2024]. doi:10.5455/OVJ.2021.v11.i3.19


AMA (American Medical Association) Style

Lavan RP, Armstrong R, Newbury H, Normile D, Hubinois C, . Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner. Open Vet J. 2021; 11(3): 458-467. doi:10.5455/OVJ.2021.v11.i3.19



Vancouver/ICMJE Style

Lavan RP, Armstrong R, Newbury H, Normile D, Hubinois C, . Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner. Open Vet J. (2021), [cited March 13, 2024]; 11(3): 458-467. doi:10.5455/OVJ.2021.v11.i3.19



Harvard Style

Lavan, R. P., Armstrong, R., Newbury, H., Normile, D., Hubinois, C. & (2021) Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner. Open Vet J, 11 (3), 458-467. doi:10.5455/OVJ.2021.v11.i3.19



Turabian Style

Lavan, Robert Philip, Robert Armstrong, Hannah Newbury, Dorothy Normile, Celine Hubinois, and . 2021. Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner. Open Veterinary Journal, 11 (3), 458-467. doi:10.5455/OVJ.2021.v11.i3.19



Chicago Style

Lavan, Robert Philip, Robert Armstrong, Hannah Newbury, Dorothy Normile, Celine Hubinois, and . "Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner." Open Veterinary Journal 11 (2021), 458-467. doi:10.5455/OVJ.2021.v11.i3.19



MLA (The Modern Language Association) Style

Lavan, Robert Philip, Robert Armstrong, Hannah Newbury, Dorothy Normile, Celine Hubinois, and . "Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner." Open Veterinary Journal 11.3 (2021), 458-467. Print. doi:10.5455/OVJ.2021.v11.i3.19



APA (American Psychological Association) Style

Lavan, R. P., Armstrong, R., Newbury, H., Normile, D., Hubinois, C. & (2021) Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner. Open Veterinary Journal, 11 (3), 458-467. doi:10.5455/OVJ.2021.v11.i3.19